CL2019002002A1 - Liposomas hiperestabilizados que mejoran busqueda de células en mitosis. - Google Patents

Liposomas hiperestabilizados que mejoran busqueda de células en mitosis.

Info

Publication number
CL2019002002A1
CL2019002002A1 CL2019002002A CL2019002002A CL2019002002A1 CL 2019002002 A1 CL2019002002 A1 CL 2019002002A1 CL 2019002002 A CL2019002002 A CL 2019002002A CL 2019002002 A CL2019002002 A CL 2019002002A CL 2019002002 A1 CL2019002002 A1 CL 2019002002A1
Authority
CL
Chile
Prior art keywords
liposomes
hyperstabilized
mitosis
cell search
improve cell
Prior art date
Application number
CL2019002002A
Other languages
English (en)
Inventor
Chang Zhi Adrian Ng
Shen-Yi Ian Cheong
Original Assignee
Temasek Life Sciences Laboratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temasek Life Sciences Laboratory Ltd filed Critical Temasek Life Sciences Laboratory Ltd
Publication of CL2019002002A1 publication Critical patent/CL2019002002A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON EL CAMPO DEL TRATAMIENTO DEL CÁNCER. MÁS ESPECÍFICAMENTE, LA INVENCIÓN SE REFIERE A LIPOSOMAS HIPERESTABLES ÚTILES PARA EL TRATAMIENTO DEL CÁNCER Y A MÉTODOS PARA TRATAR UN CÁNCER USANDO LIPOSOMAS HIPERESTABLES.
CL2019002002A 2017-01-18 2019-07-17 Liposomas hiperestabilizados que mejoran busqueda de células en mitosis. CL2019002002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762447498P 2017-01-18 2017-01-18

Publications (1)

Publication Number Publication Date
CL2019002002A1 true CL2019002002A1 (es) 2020-01-17

Family

ID=62909275

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002002A CL2019002002A1 (es) 2017-01-18 2019-07-17 Liposomas hiperestabilizados que mejoran busqueda de células en mitosis.

Country Status (18)

Country Link
US (1) US11331272B2 (es)
EP (1) EP3570818B1 (es)
JP (2) JP7232530B2 (es)
KR (1) KR20190122676A (es)
CN (1) CN110381922A (es)
AU (1) AU2018210748B2 (es)
BR (1) BR112019014718A2 (es)
CA (1) CA3050686A1 (es)
CL (1) CL2019002002A1 (es)
CO (1) CO2019008876A2 (es)
IL (1) IL268099B2 (es)
MA (1) MA47319A (es)
MX (1) MX2019008533A (es)
PH (1) PH12019501650A1 (es)
RU (1) RU2765736C2 (es)
SG (2) SG11201906539YA (es)
TW (1) TWI816656B (es)
WO (1) WO2018136002A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768117B2 (ja) * 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
AU2002334358B2 (en) * 2001-09-06 2008-02-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
RU2424792C2 (ru) * 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
WO2006049307A1 (ja) 2004-11-02 2006-05-11 National University Corporation Tokyo Medical And Dental University リポソーム及びこれを用いた細胞に対する物質注入方法
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
US20090285881A1 (en) * 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
SI2415470T1 (sl) * 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposomski sestavek
PL2419333T3 (pl) 2009-04-17 2016-07-29 3M Innovative Properties Co Płyta odgromowa ze wzorzystym przewodnikiem
EP2421506B1 (en) * 2009-04-22 2015-08-19 Emory University Nanocarrier therapy for treating invasive tumors
WO2010143972A2 (en) * 2009-06-08 2010-12-16 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
US20120301537A1 (en) * 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
ES2694154T3 (es) * 2011-10-31 2018-12-18 Mallinckrodt Llc Composiciones de liposomas combinatorias para el tratamiento del cáncer
CA2899882C (en) * 2013-02-01 2023-12-12 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes
CA2903254C (en) * 2013-03-13 2019-04-09 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy
CN109350600B (zh) * 2013-03-15 2021-10-29 台湾微脂体股份有限公司 设计脂质体水相和非水相部分的组成来控制药物的释放趋势
AU2015206628A1 (en) * 2014-01-14 2016-08-25 The Johns Hopkins University Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
JP2017516760A (ja) * 2014-04-14 2017-06-22 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 耐性がんを治療し、併用療法に用いるための薬物送達複合体
US20160175250A1 (en) * 2014-12-23 2016-06-23 Tolmar Inc. Method for Making Liposomes Containing an Active Pharmaceutical Ingredient
JP2018505224A (ja) * 2015-02-13 2018-02-22 オーピーナノ シーオー エルティーディーＯＰ Ｎａｎｏ Ｃｏ．，Ｌｔｄ． ナノ粒子を含む組成物並びに腫瘍を治療する方法

Also Published As

Publication number Publication date
US20190358161A1 (en) 2019-11-28
JP2020505451A (ja) 2020-02-20
AU2018210748A1 (en) 2019-08-29
EP3570818A1 (en) 2019-11-27
TW201828925A (zh) 2018-08-16
AU2018210748B2 (en) 2023-09-28
WO2018136002A1 (en) 2018-07-26
EP3570818B1 (en) 2023-11-01
RU2019125724A (ru) 2021-02-19
SG11201906539YA (en) 2019-08-27
IL268099B1 (en) 2024-01-01
US11331272B2 (en) 2022-05-17
RU2765736C2 (ru) 2022-02-02
IL268099A (en) 2019-09-26
KR20190122676A (ko) 2019-10-30
IL268099B2 (en) 2024-05-01
BR112019014718A2 (pt) 2020-03-10
MX2019008533A (es) 2019-12-02
JP7232530B2 (ja) 2023-03-03
CA3050686A1 (en) 2018-07-26
RU2019125724A3 (es) 2021-03-04
CN110381922A (zh) 2019-10-25
SG10202107836SA (en) 2021-08-30
CO2019008876A2 (es) 2020-01-17
EP3570818A4 (en) 2020-11-18
JP2023002702A (ja) 2023-01-10
PH12019501650A1 (en) 2020-02-24
TWI816656B (zh) 2023-10-01
MA47319A (fr) 2019-11-27

Similar Documents

Publication Publication Date Title
NI201900019A (es) Inhibidores de procesos metabólicos celulares
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
ECSP20069404A (es) Piridazinonas como inhibidoras de parp7
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2017010618A2 (es) Anticuerpos contra icos
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
EA201790737A1 (ru) Комбинированная терапия
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
ECSP15026557A (es) Compuestos y sus métodos de empleo
NI201600056A (es) Inhibidores de bromodominio
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
EA201690206A1 (ru) Терапевтически активные соединения и способы их применения
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
SG10201900564WA (en) Methods for treating cancer
CL2020000655A1 (es) Tratamiento mejorado de dermatitis atópica con tradipitant.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
GB2569488A (en) PD-1 specific aptamers